PMA device
Astron Pulsar and Pulsar-18 Stent Systems
Biotronik AG · Stent, Superficial Femoral Artery (NIP, Class III) · First FDA decision Mar 23, 2017, newest Aug 22, 2018Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
PMA pathway
Device trials
3
Naming "Astron Pulsar"
MAUDE reports
6
Brand "Astron Pulsar", since 2015
PubMed studies
5
Mentioning "Astron Pulsar"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Astron Pulsar and Pulsar-18 Stent Systems
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- Astron Pulsar and Pulsar-18 Stent SystemsPMA supplement
P160025-S005 · Decided Aug 22, 2018 · 62 days after receipt · Normal 180 Day Track No User Fee
Device type: STENT, SUPERFICIAL FEMORAL ARTERY (NIP) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Astron Pulsar", any status and sponsor, newest update first.
Biotronik, Inc.Not on our public-company list
NCT01319812 · 463 participants · Start Jul 2011 · Primary completion Sep 2015
Device: Astron Stents; Pulsar Stents · For: Peripheral Artery Disease; Peripheral Vascular Disease
Sites: Fremont, California; New Haven, Connecticut; Washington D.C., District of Columbia · 35 sites in all
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Astron Pulsar", and for the whole product code for context.
This brand
6 reports: 6 malfunction, 0 injury, 0 death
Whole product code NIP
9,363 reports: 4,911 malfunction, 4,303 injury, 147 death
Newest reports for this brand
- ASTRON PULSAR 6/30/70Malfunction
BIOTRONIK AG, BUELACH, SWITZERLAND
1028232-2022-05324 · Received Oct 18, 2022 · Event dated Sep 26, 2022
Device type: Stent, Superficial Femoral Artery (NIP)
Device problem as coded: Activation Failure
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Astron Pulsar"[tiab]. The summary above synthesizes these.
- Safety, clinical outcome, and fracture rate of femoropopliteal stenting using a 4F compatible delivery system.
Sarkadi H, Bérczi V, Kollár A, et al. · Eur J Vasc Endovasc Surg · 2015
- Performance characteristics of modern self-expanding nitinol stents indicated for SFA.
Schmidt W, Wissgott C, Andresen R, et al. · Rofo · 2011Comparative Study
- 4-French-compatible endovascular material is safe and effective in the treatment of femoropopliteal occlusive disease: results of the 4-EVER trial.
Bosiers M, Deloose K, Callaert J, et al. · J Endovasc Ther · 2013Clinical Trial, Multicenter Study
- Primary Self-EXPANDing Nitinol Stenting vs Balloon Angioplasty With Optional Bailout Stenting for the Treatment of Infrapopliteal Artery Disease in Patients With Severe Intermittent Claudication or Critical Limb Ischemia (EXPAND Study).
Schulte KL, Pilger E, Schellong S, et al. · J Endovasc Ther · 2015Comparative Study, Multicenter Study
- Midterm Results of Low-Profile Stents to Treat Atherosclerotic Iliac Artery Disease.
Troisi N, Ercolini L, Chisci E, et al. · J Endovasc Ther · 2017
Other devices of this type
Also filed under product code NIP.
- GORE VIABAHN EndoprosthesisW. L. Gore & Associates, Inc. · PMA 2022
- Supera Peripheral Stent SystemAbbott Vascular (Idef Technologies Inc) · PMA 2025
- LifeStent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2023
- Everflex Self-Expanding Peripheral Stent System (Everflex)Medtronic Vascular, Inc. · PMA 2025
- Innova Vascular Self-Expanding Stent SystemBoston Scientific Corporation · PMA 2021
- BioMimics 3D Vascular Stent SystemVeryan Medical, Ltd. · PMA 2025
- Bard Lifestent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2016
- Misago Peripheral Self-Expanding Stent SystemTerumo Medical Corporation · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.